|
Prostate News |
|
Prostate / Prostate Cancer News From Medical News Today
|
Latest Prostate / Prostate Cancer News From Medical News Today.
|
-
Cleveland BioLabs Completes Recruitment For Phase II Hormone-Refractory Prostate Cancer Trial
Cleveland BioLabs, Inc. (NASDAQ: CBLI), announced that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer. This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer.
-
Prostate Cancer Breakthrough Receives FDA Clearance
A new imaging device, eiā?¢Nav/Artemis?, now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help in the fight against prostate cancer. Artemis, designed by Eigen, a Northern California-based company known for developing innovative, affordable medical imaging solutions, will be introduced at the American Urological Association's (AUA) annual meeting May 17 - 22 in Orlando, FL.
-
Youths In Towns With Smoke-Free Restaurant Laws Appear Less Likely To Become Smokers
Young people who live in towns where regulations ban smoking in restaurants may be less likely to become established smokers, according to a report in the May issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. Many studies have examined the risk factors that lead young people to try their first cigarette, according to background information in the article.
-
Flower Power May Bring Ray Of Sunshine To Cancer Sufferers
A mini-protein found in sunflower seeds could be the key to stopping tumours spreading in prostate cancer patients, according to QUT researchers.
-
Natural History Of Pathologically Organ-Confined (pT2), Gleason Score 6 Or Less, Prostate Cancer After Radical Prostatectomy
UroToday.com - According to a report from Dr. Hernandez and colleagues at Johns Hopkins University that appears in the online version of Urology, men with prostate cancer (CaP) who undergo radical prostatectomy (RP) and have organ confined disease with Gleason score 6 or less are very unlikely to experience disease recurrence.A retrospective review identified 2,526 men between 1983 and 2005 who underwent RP, either open (2,422) or laparoscopic (104).
-
Long-Term Prediction Of Prostate Cancer
UroToday.com - In the February 20, 2008 issue of the Journal of Clinical Oncology, Dr. Ulmert and associates suggest that PSA velocity (PSAV) does not add to PSA in predicting the long-term risk of prostate cancer (CaP). The study was performed using the Malmƶ Preventive Medicine database, and included 4,907 men who had a blood sample drawn between 1974 and 1986 to investigate risk factors for cardiovascular and metabolic diseases.
-
Initial Extended Transrectal Prostate Biopsy-Are More Prostate Cancers Detected With 18 Cores Than With 12 Cores?
UroToday.com - Increasing the number of prostate biopsy cores from 10 to 18 is reported to increase the prostate cancer (CaP) detection rate from 30% to 41%. In the April 2008 issue of the Journal of Urology, Dr. Scattoni and associates retrospectively analyzed the detection rates of CaP, high-grade PIN (HGPIN), and atypical glands suggestive of carcinoma (AGSC) in patients undergoing either 18 or 12 core prostate biopsies.
-
Testosterone Levels In Benign Prostatic Hypertrophy And Prostate Cancer
UroToday.com - The introduction of PSA for the diagnosis of prostate carcinoma has undoubtedly increased the detection rate of localized tumours. As PSA has low specificity, particularly in screening programmes, surrogates are being sought e.g. PSA density, velocity or free/total ratio. Despite this, a reliable, easy to use, marker of prostate cancer still remains to be found.
-
Is Prostate Specific Antigen Velocity Selective For Clinically Significant Prostate Cancer In Screening?
UroToday.com - With the knowledge that screening for prostate cancer will lead to over detection and subsequent over treatment, the call for tests discriminating between non aggressive and aggressive prostate cancer is growing. If pre-biopsy data could make this distinction, a lot of unnecessary biopsies would be spared. The amount of prostate cancer specific antigen (PSA) increase in a year, PSA velocity (PSAV), has been suggested as a factor predictive for aggressive disease.
-
When To Wait And When To Treat? New Program Will Search For Biomarkers In Men With Prostate Cancer To Help Find An Answer
Researchers at Fred Hutchinson Cancer Research Center have a lead role in a new public/private partnership to create the first systematic surveillance program of men with prostate cancer to look for biological clues to help determine when to wait and when to treat the disease. The project was announced by the Canary Foundation and the National Cancer Institute. Peter Nelson, M.D.
|
|
News & Information 
